University of Miami's 2nd Biennial Miami Leukemia Symposium


 

Magrolimab (Formerly 5F9) is a First-in-class Macrophage Immune Checkpoint Inhibitor Targeting CD47 in R/R AML

168 views
May 14, 2020
0 Comments
Login to view comments. Click here to Login